← back to search

Barry P. Sleckman

University of Alabama at Birmingham · US
Area of research
Immunology · Molecular Biology
Research interest
Research interests include DNA Repair Mechanisms, T-cell and B-cell Immunology, Immune Cell Function and Interaction, and CRISPR and Genetic Engineering.
h-index
56
citations
12,926
works
172
NIH funding
primary concept
email

Recent publications

Beyond the Guinea Pig Myth: Understanding Complex Attitudes Toward Clinical Trials Participation in a Community Clinic
Journal of Cancer Education 2025cited by 2position: middledoi
DNA-PK promotes DNA end resection at DNA double strand breaks in G0 cells
eLife 2022cited by 25position: middledoi
The regulation of DNA end resection by chromatin response to DNA double strand breaks
Frontiers in Cell and Developmental Biology 2022cited by 16position: lastdoi
RNF2 ablation reprograms the tumor-immune microenvironment and stimulates durable NK and CD4+ T-cell-dependent antitumor immunity
Nature Cancer 2021cited by 31position: middledoi
Sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) activity is required for V(D)J recombination
The Journal of Experimental Medicine 2021cited by 26position: lastdoi
Does health literacy impact technological comfort in cancer patients?
The American Journal of Surgery 2021cited by 25position: middledoi
LIN37-DREAM prevents DNA end resection and homologous recombination at DNA double-strand breaks in quiescent cells
eLife 2021cited by 25position: lastdoi
The RNF8 and RNF168 Ubiquitin Ligases Regulate Pro- and Anti-Resection Activities at Broken DNA Ends During Non-Homologous End Joining
DNA repair 2021cited by 16position: lastdoi
DNA double-strand breaks induce H2Ax phosphorylation domains in a contact-dependent manner
Nature Communications 2020cited by 209position: middledoi
Loss of H3K36 Methyltransferase SETD2 Impairs V(D)J Recombination during Lymphoid Development
iScience 2020cited by 15position: middledoi
At the intersection of DNA damage and immune responses
Nature reviews. Immunology 2019cited by 153position: lastdoi
MRI Is a DNA Damage Response Adaptor during Classical Non-homologous End Joining
Molecular Cell 2018cited by 113position: lastdoi
The Histone Chaperones ASF1 and CAF-1 Promote MMS22L-TONSL-Mediated Rad51 Loading onto ssDNA during Homologous Recombination in Human Cells
Molecular Cell 2018cited by 109position: middledoi
Cell circuits between B cell progenitors and IL-7+ mesenchymal progenitor cells control B cell development
The Journal of Experimental Medicine 2018cited by 92position: middledoi
DNA Breaks and End Resection Measured Genome-wide by End Sequencing
Molecular Cell 2016cited by 293position: middledoi
Modeling altered T-cell development with induced pluripotent stem cells from patients with RAG1-dependent immune deficiencies
Blood 2016cited by 47position: middledoi
Catalytic and Noncatalytic Roles of the CtIP Endonuclease in Double-Strand Break End Resection
Molecular Cell 2014cited by 177position: middledoi
L-Myc expression by dendritic cells is required for optimal T-cell priming
Nature 2014cited by 79position: middledoi
Posttranscriptional regulation of c-Myc expression in adult murine HSCs during homeostasis and interferon-α-induced stress response
Blood 2014cited by 37position: middledoi
53BP1 Mediates Productive and Mutagenic DNA Repair through Distinct Phosphoprotein Interactions
Cell 2013cited by 337position: middledoi
β-Catenin induces T-cell transformation by promoting genomic instability
Proceedings of the National Academy of Sciences 2013cited by 65position: middledoi
The Ataxia Telangiectasia mutated kinase controls Igκ allelic exclusion by inhibiting secondary <i>Vκ</i> -to- <i>Jκ</i> rearrangements
The Journal of Experimental Medicine 2013cited by 45position: middledoi
The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers
Nature Immunology 2012cited by 448position: middledoi
Loss of ATM kinase activity leads to embryonic lethality in mice
The Journal of Cell Biology 2012cited by 112position: middledoi

Grants

Comprehensive Cancer Center Support Grant
NIH3P30CA013148-51S4$199,7952024–2025Contact PIRePORTER
Administrative Core
NIH5P30CA013148-48$584,5602020–2022Contact PIRePORTER
ATM FUNCTION DURING V(D)J RECOMBINATION
NIH5R01AI074953-13$423,7502008–2023Contact PIRePORTER
ATM FUNCTION DURING V(D)J RECOMBINATION
NIH2R01AI074953-12$423,7502008–2023Contact PIRePORTER
ATM FUNCTION DURING V(D)J RECOMBINATION
NIH5R01AI074953-11$419,3532008–2018Contact PIRePORTER
ATM Function During V(D)J Recombination
NIH5R01AI074953-17$371,2502008–2024Contact PIRePORTER
ATM Function During V(D)J Recombination
NIH5R01AI074953-16$371,2502008–2023Contact PIRePORTER
ATM Function During V(D)J Recombination
NIH7R01AI074953-15$371,2502008–2023Contact PIRePORTER
ATM FUNCTION DURING V(D)J RECOMBINATION
NIH5R01AI074953-14$52,5002008–2021Contact PIRePORTER
The V(D)J recombination reaction and its impact on lymphocyte development
NIH5R01AI047829-18$423,7502000–2022Contact PIRePORTER
The V(D)J recombination reaction and its impact on lymphocyte development
NIH5R01AI047829-17$423,7502000–2022Contact PIRePORTER
The V(D)J Recombination Reaction and ITS impact on Lymphocyte Development
NIH5R01AI047829-21$371,2502000–2023Contact PIRePORTER
The V(D)J Recombination Reaction and ITS impact on Lymphocyte Development
NIH7R01AI047829-20$371,2502000–2022Contact PIRePORTER
The V(D)J recombination reaction and its impact on lymphocyte development
NIH5R01AI047829-19$52,5002000–2020Contact PIRePORTER
Comprehensive Cancer Center Support Grant
NIH5P30CA013148-53$5,823,3901997–2027Contact PIRePORTER
Comprehensive Cancer Center Support Grant
NIH5P30CA013148-51$5,495,5141997–2027Contact PIRePORTER
Comprehensive Cancer Center Support Grant
NIH5P30CA013148-50$5,495,5141997–2027Contact PIRePORTER
Comprehensive Cancer Center Support Grant
NIH2P30CA013148-49$5,495,5141997–2027Contact PIRePORTER
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT
NIH5P30CA013148-47$5,103,2021997–2021Contact PIRePORTER
Comprehensive Cancer Center Core Support Grant
NIH3P30CA013148-47S6$3,827,9651997–2022Contact PIRePORTER
Administrative Core
NIH3P30CA013148-48S8$1,167,8891997–2022Contact PIRePORTER
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT
NIH3P30CA013148-48S3$742,5001997–2022Contact PIRePORTER
Leadership, Planning, and Evaluation
NIH5P30CA013148-52$457,9591997–2027Contact PIRePORTER
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT
NIH3P30CA013148-48S7$390,9991997–2022Contact PIRePORTER
COVID-19 and Its Implications for Cancer Prevention and Control: A Collaborative Effort Across Cancer Centers
NIH3P30CA013148-48S2$371,2501997–2022Contact PIRePORTER

Frequent collaborators

André Nussenzweig · Center for Cancer Research6 papers (2012–2022)Jessica K. Tyler · Cornell University6 papers (2018–2022)Bo-Ruei Chen · University of Alabama at Birmingham6 papers (2020–2022)Anthony Tubbs · Center for Cancer Research5 papers (2013–2021)Jeffrey J. Bednarski · St. Louis Children's Hospital4 papers (2013–2020)Tanya T. Paull · The University of Texas at Austin3 papers (2012–2018)Andrea Bredemeyer · Jisc3 papers (2013–2018)Faith Fowler · Enzo Life Sciences (United States)3 papers (2018–2022)David G. Schatz · Yale University3 papers (2013–2021)Yinan Wang · University of California, Riverside3 papers (2021–2021)Michel C. Nussenzweig · Rockefeller University2 papers (2013–2014)Chun-Chin Chen · Boston Medical Center2 papers (2021–2021)Baeck-Seung Lee · The University of Texas at Austin2 papers (2012–2013)Zih-Jie Shen · Cornell University2 papers (2018–2021)Nicholas Zolnerowich · National Human Genome Research Institute2 papers (2021–2022)Elsa Callén · Center for Cancer Research2 papers (2013–2020)Craig H. Bassing · UPMC Hillman Cancer Center2 papers (2013–2020)J. Daniel · Dakota State University2 papers (2012–2013)Issa Hindi · Cornell University2 papers (2018–2021)Jayanta Chaudhuri · Memorial Sloan Kettering Cancer Center2 papers (2018–2020)